Beta-Cell is developing a cell therapy for diabetes patients that experience no benefit from existing treatments. The company developed a quality controlled proprietary cell product and has an extensive track record in diabetes models (both in vitro as in vivo). Beta-Cell has been funded by VLAIO and Europe and by private investors with the Belgian-based Group Machiels as main shareholder.
We use cookies or similar technologies (e.g. pixels or social media plug-ins) to optimise your user experience on our website, among other things. In addition, we wish to use analytical and marketing cookies to personalise your visit to our website, to send targeted advertisements to you, and to give us more insight into your use of our website.
Do you consent to our use of cookies for an optimal website experience, so that we can improve our website and surprise you with advertisements? Then confirm with ‘OK’.
Conversely, would you like to set specific preferences for different types of cookies? This can be done via our Cookie Policy. Would you like more information about our use of cookies or how to delete cookies? Please read our Cookie Policy.
Sector: Drone-industrie
Sector: Health & Care sector
Sector: Technologie- en servicessector
Sector: Creatieve en innovatieve business
Sector: Smart energy
Sector: Circulaire economie
Sector: Land- en tuinbouw